
Sign up to save your podcasts
Or
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.
4.7
1414 ratings
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.
1,358 Listeners
478 Listeners
191 Listeners
2,162 Listeners
1,683 Listeners
269 Listeners
715 Listeners
258 Listeners
859 Listeners
1,264 Listeners
8,385 Listeners
244 Listeners
179 Listeners
43 Listeners
3 Listeners
76 Listeners